Open Beta
TREN
MetriLume
TREN

US marketsRNTX

SEC-sourced researchBeta

RNTX

Rein Therapeutics, Inc.

Company comparison ↗

Data passport

CIK
0001420565
Exchange
Nasdaq
Business activity
— · SIC 2834
Financial inputs
6/6
Filing date
Sep 4, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2024: 0.0000 USD; December 2025: 0.0000 USD0 USD0 USD0December 2024December 2025
RNTX · Exact amounts and source periods · USD
Period endRevenueFiling date
December 20240.0000Mar 26, 2026
December 20250.0000Mar 26, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 20250.0000-49,871,000.0000-19,361,000.000024,158,000.00007,240,000.0000Mar 26, 2026
December 20240.0000-62,883,000.0000-22,291,000.000062,190,000.00007,798,000.0000Mar 26, 2026

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenueFromContractWithCustomerExcludingAssessedTax$0December 2025Mar 26, 202610-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax$0December 2024Mar 26, 202610-K
Net incomeNetIncomeLoss-$49.87MDecember 2025Mar 26, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$19.36MDecember 2025Mar 26, 202610-K
Total assetsAssets$24.16MDecember 2025Mar 26, 202610-K
Total liabilitiesLiabilities$7.24MDecember 2025Mar 26, 202610-K

New filings

Explore methodology ↗